Study Details
Full Title
A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of PF-08052667 as a Single Agent and in Combination Therapy in Participants 18 Years of Age and Older With Bladder Cancer (C6001001)
Principal Investigator
Michael
Abern
Protocol Number
PRO00119424
NCT ID
NCT07206225
Phase
I
Enrollment Status
Open to Enrollment